Related Experiment Videos
Effects of vigabatrin on partial seizures and cognitive function
R A Grünewald1, P J Thompson, R Corcoran
1Epilepsy Research Group, National Hospital for Neurology and Neurosurgery, London, UK.
Journal of Neurology, Neurosurgery, and Psychiatry
|September 1, 1994
Summary
Vigabatrin effectively reduced complex partial seizures in patients with refractory epilepsy. While some cognitive effects were noted, the drug demonstrated sustained efficacy in seizure control over extended treatment periods.
Area of Science:
- Neurology
- Pharmacology
- Clinical Trials
Background:
- Refractory partial seizures pose a significant challenge in epilepsy management.
- New antiepileptic drugs are needed to improve seizure control and patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of vigabatrin as an add-on therapy for refractory partial seizures.
- To assess the impact of vigabatrin on seizure frequency, cognitive function, mood, and behavior.
Main Methods:
- A prospective, randomized, placebo-controlled, double-blind trial involving 45 patients with refractory partial seizures.
- Vigabatrin (1.5 g twice daily) was administered as an add-on treatment, followed by an open-label phase.
- Seizure frequency, cognitive function, mood, and behavior were monitored over baseline, double-blind, and open-label periods.
Main Results:
- Vigabatrin significantly reduced complex partial seizure frequency compared to placebo, with sustained response in over 60% of patients during long-term treatment.
- A notable reduction in motor speed and design learning test scores was observed during the initial 20 weeks of vigabatrin treatment.
- Two patients discontinued vigabatrin due to depression, which resolved upon withdrawal, indicating a potential side effect to monitor.
Conclusions:
- Vigabatrin demonstrates significant efficacy in reducing seizure frequency in patients with refractory partial seizures.
- The drug's long-term efficacy is supported by sustained response rates in responders.
- Potential cognitive side effects and mood changes, such as depression, warrant careful consideration and monitoring during vigabatrin treatment.